In November last year DSM announced that it will combine its pharmaceutical products business (DPP) with contract manufacturing organisation Patheon, bringing to an end several years of efforts to find a partner for the underperforming division .
Earlier today DSM spokesman Herman Betten told BioPharma-Reporter.com that DSM Biologics – which is part of the firm’s pharmaceutical unit – will be part of the new combined company and that the recently opened biomanufacturing facility in Brisbane would be included.
The plant, which has been operational since June last year , was constructed in partnership with the Australian Institute for Bioengineering and Nanotechnology (AIBN).
Betten also said that the official name of the combined firm – which is currently being referred to as NewCo – will be revealed when the deal is completed.
DSM’s plans for DPP also featured in the Dutch firm’s results release issued earlier today. The business is now listed as a discontinued operation.
The firm said that: “DSM Pharmaceutical Products delivered an improved performance in the quarter, with good volume growth and higher prices being reflected also in good EBITDA growth.
“This performance will support a good start for the value-creating venture with JLL Partners.”